Biomarker combination is necessary for the assessment of Gaucher disease? by Giraldo, P. et al.
Page 1 of 6
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2018;6(Suppl 1):S81atm.amegroups.com
Editorial
Biomarker combination is necessary for the assessment of 
Gaucher disease? 
Pilar Giraldo1, Laura López de Frutos2, Jorge J. Cebolla2
1Traslational Research Unit, Aragon Institute of Health Research (IISAragon), Zaragoza, Spain; 2Spanish Gaucher Disease Foundation (FEETEG), Spain
Correspondence to: Pilar Giraldo. Traslational Research Unit, Aragon Institute of Health Research (IISAragon), Zaragoza, Spain.  
Email: giraldocastellano@gmail.com.
Comment on: Jian J, Chen Y, Liberti R, et al. Chitinase-3-like Protein 1: A Progranulin Downstream Molecule and Potential Biomarker for Gaucher 
Disease. EBioMedicine 2018;28:251-60. 
Submitted Oct 22, 2018. Accepted for publication Oct 29, 2018.
doi: 10.21037/atm.2018.10.69
View this article at: http://dx.doi.org/10.21037/atm.2018.10.69
Biomarkers are useful tools to help in disease diagnosis 
and follow-up. According to the US Food & Drug 
Administration, biomarkers are defined as measurable 
elements that can be used as indicators in normal biological 
and pathological processes, or in response to an exposure 
or therapeutic interventions. Molecular, histologic, 
radiographic or physiological characteristics are some of 
those biomarkers (www.fda.gov). The term biomarker is 
currently being applied to molecular markers that define 
a specific biological status (1). Considering these factors, 
the “ideal” biomarker should fulfill susceptibility/risk, 
be reliable, and can be used for diagnosis, monitoring, 
prognosis, prediction and pharmacodynamic response.
Some useful biomarkers such as the number of BCR/ABL 
transcripts in chronic myeloid leukemia serve as sensitive 
indicators that help in the monitoring of the molecular 
response, a quantitative instrument to monitor the long-
term molecular response to therapy (2) or for example 
the serum concentration of M-component in monoclonal 
gammopathies (3).
In lysosomal storage diseases (LSD) such as Gaucher 
disease (GD) there are several available biological markers 
that are useful tools in diagnosis that offer objective 
information about the situation of the disease and in the 
follow-up to detect early complications and the stability in 
the response to treatment. However, the search for more 
reliable and accurate indicators for LSDs is an open battle 
in order to get the most sensitive, easiest to determine and 
cheapest biomarker (4). 
The study by Jian et al. (5) in the present issue of 
EBioMedicine raises some interesting information 
concerning a new biomarker [Chitinase-3-like protein 1 
(CHI3L1)] for diagnosing and following-up on GD. 
Chitinases are a family of enzymes whose main function 
is to catalyze hydrolysis of glycosidic bonds in chitin 
polymers. More than 18 different chitinases have been 
identified in mammals (6). These structures are generally 
implicated in a variety of diseases involving immune 
dysfunction or related to inflammatory environment.
Since 1994, chitotriosidase (ChT) is known as a 
biomarker in LSDs, and the first and most used biomarker 
in GD patients (7). This biomarker reflects in GD the 
presence and the quantity of Gaucher cells and therefore is 
used in the screening. From ChT description to the present, 
many studies have been carried out about its effectiveness 
and limitations as a biomarker. One of its limitations is that 
its activity is increased in plasma for different inflammatory 
processes such as atherosclerosis, ischemic heart disease, 
paludism, cancer, β-thalassemia major or myeloproliferative 
neoplasms, chronic disorders that involve activated 
macrophages although it does not reach the highest levels 
found in GD (6,8-10).
One of the problems that this biomarker shows is the 
null to reduced activity due to null alleles in the gene that 
encode them. Several studies performed on more than 600 
subjects have worked on the CHIT1 gene (MIM*600031), 
which encodes the ChT enzyme and identifies the null and/
or pseudo-deficient variants, like the changes NP_003456:p.
Glu74Lys, p.Gly102Ser, p.Gly354Arg, p.Ala442Val, or 
several complex alleles (e.g., the 4 bp deletion across the 
81
Giraldo et al. Biomarker combination is necessary for the assessment of GD
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2018;6(Suppl 1):S81atm.amegroups.com
Page 2 of 6
exon/intron-10 boundary etc.) (11). However, the most 
outstanding allele is the NM_003465:c.1049_1072 dup24 
(12,13). When this duplication is present in homozygous 
status, the subjects show total absence of ChT activity. 
In Caucasian population about 6% are homozygous and 
approximately 30–40% heterozygous for this allele (9). The 
interpretation of the fluctuations in the ChT levels must be 
individualized according to the genotype of those CHIT1 
alleles. The trend of the marker, along with the evaluation 
of other clinical parameters, is what should be studied in 
the evaluation of the activity of the disease, not its absolute 
levels.
CHI3L1 or YKL-40 lacks of chitinase activity, even 
though it is a mammalian glycoprotein that binds chitin 
polymers. This pro-inflammatory marker increases for 
auto-immune diseases as rheumatoid arthritis and different 
rheumatic process, pulmonary sarcoidosis, among others 
(5,6). CHI3L1 binds to interleukin-13 (IL-13) receptor α2 
and exerts its biological function by activating downstream 
mitogen-activated protein kinase B/AKT. Wnt/β-catenin 
signaling (14) is able to suppress the alpha tumor necrosis 
factor (TNFα) and IL-1-induced secretion of matrix 
metalloproteases and IL-8 in both human skin fibroblasts 
and articular chondrocytes. Jian et al. (5) in their study 
propose CHI3L1 to be a novel downstream molecule 
with potential to be used as a biomarker for screening of 
the GD and examining the therapeutic effects of new GD 
drugs. The fact that these markers are sensitive during 
inflammatory processes may have the added value of 
guiding the inflammatory state underlying the LSD.
Patients suffering from GD live with the fear of 
developing osteoarticular complications.  Finding 
biomarkers that can predict the appearance of bone 
complications is of great interest. This would help detect 
the risk of them appearing, allowing us to make appropriate 
therapeutic decisions, like the dose to be administered and 
maintained with enzymatic replacement therapy (ERT) 
or whether or not to switch to oral treatment. Another 
desirable goal is to find a good marker/predictor for the 
development of complications such as gallbladder stones, 
the appearance of neoplasms or Parkinson’s disease as more 
frequent complications related to GD.
There are other biomarkers that only specifically reflect 
the accumulation of substrates, such as glucosylsphingosine 
(Lyso-Gb1), the deacylated form of glucosylceramide, which 
was first described in 1982 by Nilsson and Svennerholm (15) 
who found this molecule in high concentration in the brain 
and cerebellum of GD patients affected by the neurological 
forms. Its concentration in the plasma is 200 times greater 
than control samples for subjects affected by GD type 1 
(GD1) versus controls (16). Lyso-Gb1 levels seem to be 
related to the genotype of GBA (MIM*606463), being 
higher in patients with severe mutations. This biomarker is 
highly specific from GD, shown high levels in patients and 
normal levels in carriers and other LSDs even Krabbe disease 
when a suitable chromatographic method is applied (16). 
Lyso-Gb1 shows a wide range of normal/pathological values 
due to methodological variability (16-18). In a few studies 
concerning response to therapy, it can be observed that 
the amount of this biomarker in plasma rapidly decreases 
once the ERT is started, and its discontinuation causes a 
significant increase, being detected earlier in the 3 weeks of 
the interruption than in the 10 weeks in the ChT activity (16). 
Nowadays the experience using this biomarker in the clinical 
practice is limited, so is difficult to know its real usefulness. 
Lyso-Gb1 appears to induce tissue inflammation in 
mice (19) but it is still unknown if it is tissue specific and the 
modifications in inflammatory response that occurs after 
treatment. Despite all this, Lyso-Gb1 promises to be useful 
biomarker in patients without ChT activity. 
Another accredited biomarker useful in LSD is the 
chemokine CCL18/PARC, which is an inflammatory 
marker produced by T lymphocytes and monocytes, first 
described by Boot et al. in 2004 (20) as a peptide that was 
first detected in plasma of GD subjects. Comparing the 
mass spectra profiles (SELDI-TOF) significant differences 
between healthy individuals and those affected by GD were 
found, being these levels almost 30 times higher in the 
latter. Likewise, Boot et al. verified that its levels decreased 
during treatment, correlating this reduction with observed 
reduction in ChT activity (20). This cytokine was quantified 
by immunoquantification methods in plasma, showing that 
its variations are not as early and sensitive as ChT. During 
the period of shortage of ERT suffered in 2009, it could be 
observed that after 6 months of discontinued imiglucerase 
therapy ChT activity increased by 35% (P<0.03), while 
the CCL18/PARC concentration only was increased by an 
average of 8.2% (P<0.08) (21).
Therefore, it can be stablished that there is correlation 
between the concentration of CCL18/PARC and ChT 
activity, but also that this is markedly high in other entities 
such as atherosclerosis, active C hepatitis, pneumonitis, 
allergic hypersensitivity, sepsis, ovarian carcinoma, 
rheumatoid arthritis, Niemann-Pick disease, β-thalassemia 
and others, being able to exist overlap between them (20).
Ferritin was another one of the biomarkers used in the 
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follow-up of GD. Ferritin is a protein that binds to iron in 
tissues, storing it in a biologically available form for vital 
cellular processes as protecting proteins, lipids and DNA 
from their potential toxicity. Iron homeostasis is controlled 
by a circulating peptide, hepcidin, whose production in 
the liver is influenced by inflammatory cytokines (22). 
Glucosylceramide accumulation in macrophages induces 
an inflammatory response that produces deregulation 
in iron recycling and cytokine release. Data collected in 
the Spanish Registry of GD revealed that up to 60% of 
patients with GD1 have hyperferritinemia (23), which has 
been associated by some authors with the severity of this 
disease (24). Hyperferritinemia reverts with ERT with no 
relationship stablished between this and the mutations in 
the hemochromatosis gene. It has been speculated that 
the failure of iron control mechanisms contributes to the 
development of some pathological conditions such as 
inflammation, neurodegeneration, metabolic disorder and 
cancer, conditions that frequently occur in GD (24,25).
In some studies, a reduction in the serum concentration 
of ferritin after months in ERT has been observed (25,26). 
Although hyperferritinemia occurs in a majority of GD1 
patients, its value as a biomarker of the disease, unlike 
ChT and CCL18/PARC, is secondary, is only found in 
association with the severity of the disease and increase 
of some cytokines (27). Stein et al. studied the correlation 
between ChT, CCL18/PARC and ferritin, finding that ChT 
and CCL18/PARC were clearly superior as biomarkers of 
GD to ferritin (27).
The angiotensin-converting enzyme (ACE) has high 
concentration in plasma of GD patients compared to the 
values in the controls. ACE is a membrane protein involved 
in the homeostasis of blood pressure, whose active sites 
are directed to the extracellular spaces; its presence in 
plasma comes from the endothelium. In healthy subjects, 
circulating levels are usually very low, with a considerable 
variation range between individuals. ACE increase in serum 
of patients with GD was first described about 40 years ago 
and it is considered to be produced in excess by Gaucher 
cells. However, this biomarker is not specific, so it also 
appears increased when suffering from other diseases, such 
as sarcoidosis or other inflammatory process. Nevertheless, 
overlapping occurs between GD patients and controls (28). 
The bone affection is present quite frequently in types 
1 and 3 of GD, compromising the functionality and life 
quality of patients. Hence, it would be of great importance 
to have specific markers to predict this affection. Despite 
of having numerous biomarkers related both to osteoclasts 
(markers of bone resorption) and to osteoblasts (markers 
of bone formation), no great advances have been made 
in determining their specificity in GD. Bone alkaline 
phosphatase which is related to bone mineralization, 
osteocalcin, the major protein of the non-collagenous bone 
matrix whose concentration is subject to the circadian 
rhythm and the procollagen peptides, was released to 
the bloodstream after the secretion of procollagen by 
osteoblasts (29).
The activity of isoenzyme 5b of acid phosphatase 
(TRAP5b) marker during bone resorption, which plays a 
critical role in the degradation of type I collagen by the 
osteoclast, was found at high levels for the first time by 
Tuchman in 1959 in GD patients. This concluded that the 
rise of acid phosphatase in serum, unlike acid phosphatase 
of prostate origin or erythrocyte origin, which is not 
inhibited by L-tartrate, formaldehyde or copper ions, 
could be considered as a suspicious biomarker for GD (30). 
Elevation of TRAP5b activity occurs in all three subtypes 
of GD. However, it is also at high levels in the plasma of 
patients with Niemann-Pick disease, osteopetrosis, multiple 
myeloma among others. 
The markers of bone metabolism are complex and their 
concentration depends on multiple factors: the fasting 
period, circadian rhythm, phase of the menstrual cycle, rest-
exercise, diet, season, drugs intake and habits. This creates 
great biological variability, making their use in clinical 
practice rather controversial and is not recommended to use 
during the follow-up of patients in ERT (29).
When looking for a specific biomarker for bone disease, 
several cytokines were evaluated. These substances are 
secreted by activated macrophages and T lymphocytes, and 
have been extensively studied in plasma and/or serum of 
patients with GD1.
High levels of IL-1β, the antagonist receptor of 
IL-1, IL-6, TNFα and the soluble IL-2 receptor (31) 
were found, 2- to 5-fold increase in the antigen activator of 
monocyte differentiation of macrophages (CD14) and 2 to 8 
times that of the macrophage colony formation stimulating 
factor (M-CSF) (32). Studies carried out in a cohort of 
83 GD1-patients compared to controls have revealed an 
increase in the levels of proinflammatory cytokines IL-
4, 1-α and 1-β macrophage inflammatory proteins (MIP) 
and TNFα, as well as the reduction of anti-inflammatory 
cytokines such as IL-10 and IL-13 (33). The studies 
performed in a mouse model with the neurological form of 
GD show high levels of mRNA expression up to 30-fold in 
the proinflammatory cytokines IL-1β, TNFα, TNF receptor 
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1 and M-CSF on the gray matter of brain tissue (34), 
and the increase is greater when the disease progresses. 
Similarly, cytokines CCL2/MCP-1, CCL3/MIP1α and 
CCL5/RANTES, which regulate the infiltration of immune 
cells and the crossing of the blood-brain barrier, were found 
to be between 120 and 400 times larger.
The TNFα, is a cytokine produced by macrophages, 
necessary for adhesion molecule expression and leukocyte 
recruitment where inflammation occurs. It is involved 
in several physiological and pathological processes, such 
as bone resorption. There is a contradiction between 
previously published results on their expression in the 
plasma of GD-suffering patients, probably due to the 
limited number of patients showing significant expression 
differences between patient and control samples (20,22) 
in contrast to the study by Altarescu et al. in 25 GD1 
patients, 4 GD2 and 1 GD3 demonstrated a significant 
increase in TNFα plasma concentration (35) nevertheless 
the highest levels of TNFα corresponded to patients with 
neuronopathic forms. It has been indicated that TNFα 
changes the expression of ion channels and membrane 
potentials of oligodendrocytes in vitro, produces the 
breakage of myelin and necrosis of oligodendrocytes. 
These authors analyzed the variation of TNFα levels during 
ERT, observing a decrease in TNFα levels, becoming more 
pronounced the higher the concentration was before the start 
of treatment. That supports the idea that there is a causal 
relationship between the disease and the secretion of this 
cytokine. Subsequent studies have analyzed the relationship 
between TNFα levels and the genotype of patients for the 
polymorphism NG_007462.1:g.4682G>A (rs1800629), 
located in the promoter region of the TNF gene, finding 
significant differences between serum TNFα levels among 
patients homozygous for said polymorphism (A/A). The 
lowest values correspond to these and heterozygotes (A/
G), which present the highest expression values (35). Out of 
all these data it was concluded that the genetic variability in 
TNFα could be associated to the severity in the GD, so that 
the presence of only one mutated allele would be associated 
with greater severity of the disease. However, it does not 
correlate with the ChT activity, always limited by the small 
number of patients analyzed.
IL-6 is a paracrine regulator of plasma cell growth in 
bone marrow. Increased levels have also been detected 
in the serum of GD patients (33). IL-6 levels are greatly 
increased in patients with multiple myeloma. This neoplasia 
is more frequent in patients with GD. Said cytokine induces 
maturation of B cells, T lymphocyte growth and the hepatic 
response for acute phase reactants, so it has been suggested 
that it may play an important role in the expression of GD 
and its association with multiple myeloma. In addition, it is 
a potent modulator of bone resorption, so that its increase 
in GD patients’ plasma could be related to the development 
of bone disease. 
The β-hexosaminidase activity is high (especially 
the isoform B) in most patients suffering from GD, 
with an average value of approximately twice its normal 
concentration. Its values decrease during the ERT, reaching 
normal levels in some cases after a few months in treatment. 
Likewise, levels of α-mannosidase, β-glucuronidase, 
N-acetylglucosaminidase and in some cases—even if just 
slightly—β-galactosidase increase has been described. 
Although the reason for this decompensation of other 
lysosomal hydrolases is unknown. It is possible that they 
are compensatory processes that attempt to eliminate 
accumulated excess glucocerebroside, being secreted by 
Gaucher cells or other activated cells (32).
Recently a new regulator of GD through direct binding 
to glucocerebrosidase has been identified. Progranulin 
(PGRN) is a growth factor with multiple functions, 
including promoting cell proliferation, stimulating wound 
healing and facilitating the delivery of glucocerebrosidase 
to lysosome (28). GRN (MIM*138945) gene mutations are 
widely present in GD patients where serum levels of PGRN 
are significantly reduced (36). In a gene array screening 
from T cells of WT and PGRN KO mice, Chitinase-3 like 
family members (CHI3L1, CHI3L3, CHI3L4) are up-
regulated in PGRN KO mice. CHI3L1 was confirmed to 
have the strongest induction among the three members, 
especially in the spleen. The analysis among serum levels of 
ChT, PGRN, and CHI3L1 have demonstrated that PGRN 
levels correlate positively to CHI3L1 and ChT in GD 
patients. A weaker correlation is observed between PGRN 
and CHI3L1 in healthy controls, but none is observed 
between PGRN and ChT in healthy controls and the 
disease
Conclusions
GD is, perhaps, the LSD that has the best monitoring 
biomarkers. However, the “ideal” biomarker—which reflects 
all the aspects of the disease—in which the activity of the 
cells correlates with the clinical severity of the disease, 
efficiency of the treatment and that predicts complications 
has not been found yet.
The ChT activity is a good biological marker, easy 
Annals of Translational Medicine, Vol 6, Suppl 1 November 2018 Page 5 of 6
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2018;6(Suppl 1):S81atm.amegroups.com
to measure and economical, which correlates with the 
burden of the disease and is modified with the treatment 
applied, therefor it is a useful tool to monitor the treatment 
response. The limitation that this biomarker has is that 6% 
of the population lacks of ChT activity so it cannot be used 
as a marker in these patients. In addition, it is not possible 
to compare or predict the occurrence of bone complications 
involved in the disease.
The quantification of plasma Lyso-Gb1 only specifically 
reflects the accumulation of substrate, that is not uniform 
in different compartments and tissues. Also, the amount 
of accumulation does not show the underlying degree of 
inflammation which could be related to complications 
related to the immune system or neurological involvement.
Alternatively, CCL18/PARC, ACE, TRAP5b and ferritin 
are also inflammatory biomarkers that inform about the 
grade of immune stimulation.
The authors of the study “Chitinase-3-like Protein 1: A 
Progranulin Downstream Molecule and Potential Biomarker for 
Gaucher Disease” are proposing that the identification and 
characterization of this new molecule may lead to innovative 
diagnostic biochemical approaches for lysosomal disorders, 
in particular GD, and may be also used as a biomarker for 
evaluating the therapeutic effects of new treatments and 
to determine whether CHI3L1 is a better biomarker than 
those currently employed, in particular ChT. 
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